VolitionRx
VNRX
9 hedge funds and large institutions have $4.25M invested in VolitionRx in 2015 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
387% more capital inflows, than outflows
Capital inflows: $448K | Capital outflows: $92K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
29% more funds holding
Funds holding: 7 → 9 (+2)
0.48% more ownership
Funds ownership: 4.77% → 5.25% (+0.48%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$176K |
| 2 |
Millennium Management
New York
|
+$103K |
| 3 |
Virtu KCG Holdings
New York
|
+$57.7K |
| 4 |
Morgan Stanley
New York
|
+$55.7K |
| 5 |
Bank of New York Mellon
New York
|
+$39.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Suisse
Zurich,
Switzerland
|
-$47K |
| 2 |
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$45K |
VNRX Hedge Fund Activity: Q3 2015 in Review
9 of the 3,589 institutional investors tracked by Wall St. Rank reported a position in VolitionRx (VNRX) for Q3 2015, worth a combined $4.25M — up 26% from $3.38M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VNRX positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $176K. The largest seller was Credit Suisse, exiting entirely with an estimated $47K sold.
- 9 institutional investors held VolitionRx (VNRX) as of Q3 2015, up from 7 in Q2 2015.
- Funds reported $4.25M of VolitionRx stock for Q3 2015, up 26% quarter-over-quarter.
- 4 funds opened new VolitionRx positions in Q3 2015 and 2 closed out, a net change of +2 holders.
- The largest VolitionRx buyer in Q3 2015 was Goldman Sachs, an estimated $176K added.
- The largest VolitionRx seller in Q3 2015 was Credit Suisse, an estimated $47K sold.
Based on aggregated 13F filings for Q3 2015.